2.7  0.27 (11.11%)		10-24 16:00
Open: 2.59 High: 2.78 Volume: 865,239		Pre. Close: 2.43 Low: 2.57 Market Cap: 58(M)

Short term
Mid term
Targets	6-month :	3.56	1-year :	4.16
Resists	First :	3.04	Second :	3.56
Pivot price	2.43
Supports	First :	2.51	Second :	2.18
MAs	MA(5) :	2.47	MA(20) :	2.43
	MA(100) :	2.53	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	49.7	D(3) :	42.3
RSI	RSI(14): 59.7
52-week	High :	8.93	Low :	1.78

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MDCX ] has closed above the upper band by 18.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 72.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.78 - 2.79	2.79 - 2.8
Low:	2.54 - 2.56	2.56 - 2.57
Close:	2.68 - 2.7	2.7 - 2.72

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Fri, 17 Oct 2025
Medicus Pharma Completes Share Sales to YA II PN - TipRanks

Mon, 29 Sep 2025
$2B Market Opportunity: FDA Supports Medicus Pharma's Novel Skin Cancer Treatment Using Dissolving Microneedles - Stock Titan

Tue, 02 Sep 2025
$6 Billion Market Potential: Medicus Pharma Acquires Breakthrough Prostate Drug Developer Antev with FDA Studies - Stock Titan

Wed, 20 Aug 2025
Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA) - FinancialContent

Fri, 04 Jul 2025
Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment - Seeking Alpha

Mon, 02 Jun 2025
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering - Newsfile

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	20 (M)
Shares Float	11 (M)
Held by Insiders	36 (%)
Held by Institutions	15 (%)
Shares Short	426 (K)
Shares Short P.Month	382 (K)

EPS	-1.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-103 %
Return on Equity (ttm)	-352.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-2.07
PEG Ratio	0
Price to Book value	13.5
Price to Sales	0
Price to Cash Flow	-3.53

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.